The companies also announced that Xoma has successfully completed the Human Engineering of AV-299. This agreement further strengthens the collaboration between the companies that began with the humanization
The initial phase Ib trial will evaluate NOV-205 versus placebo as monotherapy in 30 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus
The typical EMEA review period for this centralized procedure is approximately 12 months. In conjunction with this filing, the company has also announced its intent to seek a
Orphan drug designation is intended to encourage research and development into new therapies for rare diseases. Orphan drug designation also provides eligibility for a special seven-year period of
The company said that its retail business was on track with continued expansion in the international and UK community pharmacy businesses. Good weather in July and a particularly
Adherex commented that as 5-FU is one of the most commonly prescribed anti agents in the world, it expected the combination of eniluracil + 5-FU to be rapidly
Under the terms of the agreement, Millennium will commence within ten days a cash tender offer to acquire the shares of AnorMed stock at a price of $12
In the phase III clinical trial, eight out of 10 patients receiving Remicade induction therapy achieved 75% improvement in psoriasis by week 10. Similar results were seen in
Medivation expects patient dosing to begin in early October. Dimebon has been shown to prevent the death of brain cells in preclinical models of Alzheimer’s disease and Huntington’s
New phase II data presented demonstrated that up to 77% of patients taking once-daily oral FTY720 remained free of relapses over two years. They also maintained a low
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.